The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Cancer Recurrence, Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym:

Pin It on Pinterest